Healthcare / Diagnostics & ResearchSES
$0.38
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.5M · quality 88.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58M
P/E
6.3x
↓EV/EBITDA
5.2x
↓ROE
40.3%
↑Gross Margin
84.3%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.4%
FCF CAGR
-0.4%
FCF margin
35.3%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.1M · net income $8.4M · FCF $6.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.1M | $19.1M | $18.8M | $19.1M | $19.3M |
| Net Income | $8.4M | $8.4M | $3.8M | $2.9M | $6.4M |
| EBITDA | $10.9M | $10.9M | $7.0M | $6.0M | $9.6M |
| EPS | 0.05 | 0.05 | 0.03 | 0.02 | 0.04 |
| Gross Margin | 84.3% | 84.3% | 84.9% | 86.2% | 86.3% |
| Operating Margin | 37.0% | 37.0% | 37.4% | 42.5% | 44.5% |
| Net Margin | 44.2% | 44.2% | 20.4% | 15.3% | 33.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.30 | 0.45 | 0.57 |
| Current Ratio | 1.96 | 1.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.7M | $6.7M | $6.2M | $6.5M | $6.8M |
| Returns | |||||
| ROE | 40.3% | 40.3% | 26.2% | 24.1% | 58.0% |
| Valuation | |||||
| P/E | 6.33 | 6.33 | 10.67 | 20.41 | 10.98 |
| EV/EBITDA | 5.16 | 5.16 | 5.43 | 9.87 | 7.22 |
| P/B | 2.79 | 2.79 | 2.80 | 4.92 | 6.36 |
| Growth & Yield | |||||
| Revenue Growth | 1.6% | 1.6% | -1.4% | -1.2% | — |
| EPS Growth | 117.0% | 117.0% | 29.1% | -54.2% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-15.0%
EPS terminal req.
$0.03
Spread vs growth
132.0%
5Y implied EPS CAGR
-5.8%
EPS terminal req.
$0.04
Spread vs growth
122.8%
10Y implied EPS CAGR
1.8%
EPS terminal req.
$0.07
Spread vs growth
115.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.6%
Start / end P/E
11.7x → 6.9x
EPS bridge
0.03 → 0.05
Residual
-47.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.